Who
Bain Capital Life Sciences Investors, LLC
10% owner
Company insider
Files Form 4 as: 10% owner, Rapid Micro Biosystems; 10% owner, Heartflow; 10% owner, Kailera Therapeutics; 10% owner, Olema Pharmaceuticals; 10% owner, NewAmsterdam Pharma Company; 10% owner, Annexon; 10% owner, Replimune Group; 10% owner, Marinus Pharmaceuticals.
In numbers
- Trades disclosed
- 32
- Buys
- 5
- Sells
- 7
- Bought
- $36.9M
- Sold
- $181.1M
- Companies
- 8
- Companies where not an officer
- 8
- First trade
- 15 Dec 2017
- Last trade
- 20 May 2026
- Last filed
- 22 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 May 2026filed 22 May 2026 | RPID Rapid Micro Biosystemsoption or derivative · Life-science tools | SEC FORM 4 Code P | —1,463,000 | filing |
| 20 May 2026filed 22 May 2026 | RPID Rapid Micro Biosystemsoption or derivative · Life-science tools | SEC FORM 4 Code P | —1,463,000 | filing |
| 20 May 2026filed 22 May 2026 | RPID Rapid Micro Biosystemsoption or derivative · Life-science tools | SEC FORM 4 Code P | —1,463,000 | filing |
| 30 Apr 2026filed 30 Apr 2026 | HTFL HeartflowMedical Devices | SEC FORM 4 Sold | $26.0M892,533 at $29.18 | filing |
| 30 Apr 2026filed 30 Apr 2026 | HTFL HeartflowMedical Devices | SEC FORM 4 Sold | $1.7M56,224 at $30.05 | filing |
| 29 Apr 2026filed 30 Apr 2026 | HTFL HeartflowMedical Devices | SEC FORM 4 Sold | $23.4M797,133 at $29.37 | filing |
| 28 Apr 2026filed 30 Apr 2026 | HTFL HeartflowMedical Devices | SEC FORM 4 Sold | $7.8M254,110 at $30.51 | filing |
| 20 Apr 2026filed 20 Apr 2026 | KLRA Kailera TherapeuticsBiotechnology | SEC FORM 4 Code C | —16,875,000 | filing |
| 20 Apr 2026filed 20 Apr 2026 | KLRA Kailera TherapeuticsBiotechnology | SEC FORM 4 Code C | —4,145,768 | filing |
| 20 Apr 2026filed 20 Apr 2026 | KLRA Kailera TherapeuticsBiotechnology | SEC FORM 4 Bought | $25.0M1,562,500 at $16.00 | filing |
| 20 Apr 2026filed 20 Apr 2026 | KLRA Kailera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —16,875,000 at $0.00 | filing |
| 20 Apr 2026filed 20 Apr 2026 | KLRA Kailera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —4,145,768 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | HTFL HeartflowMedical Devices | SEC FORM 4 Sold | $56.1M2,000,000 at $28.05 | filing |
| 4 Feb 2026filed 6 Feb 2026 | HTFL HeartflowMedical Devices | SEC FORM 4 Sold | $56.1M2,000,000 at $28.05 | filing |
| 10 Jan 2025filed 13 Jan 2025 | OLMA Olema Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code J | —3,500,000 | filing |
| 10 Jan 2025filed 13 Jan 2025 | OLMA Olema PharmaceuticalsBiotechnology | SEC FORM 4 Code J | —3,500,000 | filing |
| 8 Jan 2025filed 13 Jan 2025 | OLMA Olema PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $1.7M300,000 at $5.76 | filing |
| 13 Dec 2024filed 17 Dec 2024 | NAMS NewAmsterdam Pharma Companyoption or derivative · Biotechnology | SEC FORM 4 Code P | $40.0M1,632,653 at $24.50 | filing |
| 25 May 2023filed 30 May 2023 | ANNX AnnexonBiotechnology | SEC FORM 4 Bought | $639K300,000 at $2.13 | filing |
| 19 Jul 2021filed 21 Jul 2021 | RPID Rapid Micro BiosystemsLife-science tools | SEC FORM 4 Code C | —6,999,998 | filing |
News
Analyzing Weave Communications (NYSE:WEAV) & Heartflow (NASDAQ:HTFL)HTFL · tickerreport.com · 9 Oct 2026Head to Head Comparison: Weave Communications (NYSE:WEAV) and Heartflow (NASDAQ:HTFL)HTFL · themarketsdaily.com · 7 Oct 2026
0 headlines in the last 90 days name Bain Capital Life Sciences Investors, LLC; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.